prikaz prve stranice dokumenta Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome
  Preuzmi
PDF 478.65 KB
Znanstveni rad - Izvorni znanstveni rad
Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome
Hematology, 21 (2016), 3; 170-174. https://doi.org/10.1080/10245332.2015.1101964
Lucijanić, Marko; Pejša, Vlatko; Mitrović, Zdravko; Štoos-Veić, Tajana; Livun, Ana; Jakšić, Ozren; Vasilj, Tamara; Piršić, Mario; Hariš, Višnja; Prka, Željko; Kušec, Rajko

Citirajte ovaj rad

Lucijanić, M., Pejša, V., Mitrović, Z., Štoos Veić, T., Livun, A., Jakšić, O. ... Kušec, R. (2016). Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome. Hematology, 21. (3), 170-174. doi: 10.1080/10245332.2015.1101964

Lucijanić, Marko, et al. "Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome." Hematology, vol. 21, br. 3, 2016, str. 170-174. https://doi.org/10.1080/10245332.2015.1101964

Lucijanić, Marko, Vlatko Pejša, Zdravko Mitrović, Tajana Štoos Veić, Ana Livun, Ozren Jakšić, Tamara Vasilj, et al. "Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome." Hematology 21, br. 3 (2016): 170-174. https://doi.org/10.1080/10245332.2015.1101964

Lucijanić, M., et al. (2016) 'Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome', Hematology, 21(3), str. 170-174. doi: 10.1080/10245332.2015.1101964

Lucijanić M, Pejša V, Mitrović Z, Štoos Veić T, Livun A, Jakšić O, i sur.. Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome. Hematology [Internet]. 04.2016. [pristupljeno 21.01.2025.];21(3):170-174. doi: 10.1080/10245332.2015.1101964

M. Lucijanić, et al., "Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome", Hematology, vol. 21, br. 3, str. 170-174, Travanj 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:456350. [Citirano: 21.01.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:456350
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome
AutorMarko Lucijanić
AutorVlatko Pejša
AutorZdravko Mitrović
AutorTajana Štoos-Veić
AutorAna Livun
AutorOzren Jakšić
AutorTamara Vasilj
AutorMario Piršić
AutorVišnja Hariš
AutorŽeljko Prka
AutorRajko Kušec
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
OBJECTIVES: The recent availability of potent oral iron chelators is renewing an interest in the assessment of the possible impact of HFE genetics in MDS. ----- METHODS: Thirty six newly diagnosed patients with MDS were studied for parameters of iron metabolism in addition to C282Y and H63D mutations of the HFE gene. ----- RESULTS: Mutations were present in 11 out of 36 patients (31%), which were not different from our general population and were equally distributed among MDS subtypes. Mutated patients had higher ferritin levels (P = 0.039) and lower TIBC (P = 0.018). Ferritin was found to be higher for the untransfused mutated patients (P = 0.017), but not for transfusion-dependent patients in whom ferritin levels correlated significantly with the number of blood units received (P = 0.04). There was no difference in the number of blood units received between the mutated and wild type patients. A new observation made was that the mutated patients had a lower overall survival in addition to a poorer leukemia free survival (LFS) (P = 0.004 and P = 0.003, respectively). ----- DISCUSSION: The HFE gene mutations are not more frequent in MDS patients. Iron overload in mutated patients was higher but there was no correlation found using supportive therapy for anemia. The effect of mutations on survival could be mediated by changes in iron metabolism. ----- CONCLUSION: The HFE genotype may predict MDS prognosis and there is a need for further studies. It remains a challenging question if HFE mutated MDS patients should be considered for potent iron chelation therapy.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaHematology
Brojčani podacivol. 21, br. 3, str. 170-174
p-ISSN1024-5332
DOIhttps://doi.org/10.1080/10245332.2015.1101964
URN:NBNurn:nbn:hr:105:456350
Datum objave publikacije2016-04
URL dokumentahttps://doi.org/10.1080/10245332.2015.1101964
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 08:58:54